
    
      Subjects will receive benralizumab every 4 weeks for three doses followed by a fourth dose 8
      weeks later. On baseline and after 4, 16 and 20 weeks, subjects will be assess for airway
      responsiveness to exercise and exercise tolerance.
    
  